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The present study aimed to identify commonalities in the microRNA (miRNA) expression profiles of the brain ischemic penumbra 
and the blood after hyperacute ischemic stroke and then to address whether the miRNA profile of blood has potential usefulness 
as a diagnostic biomarker of hyperacute ischemic stroke. Blood was collected from the jugular vein 4 h after permanent middle 
cerebral artery occlusion (pMCAO). After venous blood was collected, the rats were decapitated immediately, and brain ischemic 
penumbra samples were collected. Hematoxylin and eosin staining was used to observe the histopathological changes. Penumbra 
and blood miRNAs were measured by miRNA microarray and real‑time polymerase chain reaction (PCR) analysis. MicroRNA 
profiles differed between hyperacute ischemic stroke and sham‑operated rats. The expression of some miRNAs changed by more 
than 1.5‑fold in the penumbra and blood 4 h after pMCAO; among those miRNAs, several were upregulated and several were 
downregulated. MiR‑223‑3p was found to be highly expressed in both the penumbra and the blood 4 h after pMCAO, and let‑7b‑3p 
was found to have low expression in both the penumbra and the blood 4 h after pMCAO. Moreover, miR‑223‑3p and let‑7b‑3p 
expression in blood and brain ischemic penumbra were positively correlated. The results show that select blood miRNAs may 
correlate with miRNA changes in the penumbra in a rat model of hyperacute ischemic stroke. Our findings suggest the potential 
usefulness of blood miR‑223‑3p and let‑7b‑3p as noninvasive biomarkers for the diagnosis of hyperacute ischemic stroke.
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INTRODUCTION
Stroke is a leading cause of death and long‑term dis‑
ability worldwide, and most strokes are of ischemic ori‑
gin (Goldstein et al., 2001). Intravenous tissue plasmino‑
gen activator (t‑PA) remains the only U.S. Food and Drug 
Administration‑approved treatment for acute ischemic 
stroke (National Institute of Neurological of Neurolog‑
ical Disorders and Stroke rt‑PA Stroke Study Group, 
1995). Although thrombolytic treatment within 4.5 h of 
ischemic stroke onset greatly improves the clinical out‑
come, only a small number of patients with hyperacute 
ischemic stroke receive thrombolytics (National Insti‑
tute of Neurological Disorders and Stroke rt‑PA Stroke 
Study Group, 1995; Wang et al., 2000). The chief limita‑
tion of current thrombolytic treatment for ischemic 
stroke is the narrow time window for safe and effective 
treatment. In addition to these time constraints, diag‑
nostic uncertainty limits the use of thrombolytic treat‑
ment in many cases of hyperacute ischemic stroke (Bar‑
ber et al., 2001). At present, the diagnosis of hyperacute 
ischemic stroke depends on clinical examination and 
neuroimaging techniques. Blood samples can be easily 
collected from patients with ischemic stroke in clinical 
practice and used for clinical diagnosis in general; how‑
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ever, there are no reliable circulating biomarkers for 
the diagnosis of hyperacute ischemic stroke. 
Previous studies have shown that hundreds of dif‑
ferent genes changed in the blood of ischemic stroke 
patients at both DNA and RNA levels (Tan et al., 2009; 
Sorensen et al., 2014; Zhang et al., 2014; Li et al., 2015). 
Therefore, further research is necessary to better un‑
derstand the molecular biology of hyperacute ischemic 
stroke and identify potential circulating blood bio‑
markers for early diagnosis and accurate evaluation.
MicroRNAs (miRNAs) are a novel class of small, non‑
coding RNAs that are widely expressed in mammalian 
cells and negatively regulate gene expression at the 
post‑transcriptional level by binding to the 3‑untrans‑
lated regions (3′‑UTRs) of their target mRNAs (Bartel, 
2004; Guo et al., 2010). Over the past decade, many stud‑
ies have demonstrated that miRNAs are associated with 
the occurrence and development of various diseases 
(Lu et al., 2005; Liu et al., 2010; Li and He 2012; Di Grego‑
li et al., 2017). Some recent studies have demonstrated 
that the expression patterns of miRNAs are altered in 
patients with various neurological disorders, including 
ischemic stroke (Tan et al., 2009; Dewdney et al., 2018).
Changes in miRNA levels are closely correlated with 
the pathological processes of ischemic stroke – oxi‑
dative damage, excitotoxicity, inflammatory reaction, 
cortical neurogenesis, neuronal cell death, brain edema 
formation and blood–brain barrier disruption (Jeya‑
seelan et al., 2008; Nielsen et al., 2009; Yin et al., 2010; 
Rink and Khanna 2011; Tan et al., 2011; Li et al., 2017). 
It is generally believed that miRNAs released from cir‑
culating cells or damaged cells result in an increase 
in blood miRNA levels (Mayr et al., 2013). On the ba‑
sis of the above data, we believe that miRNA expres‑
sion profiles may be very helpful for earlier diagnoses, 
as well as for achieving a better understanding of the 
pathogenesis of hyperacute ischemic stroke.
To date, few studies have focused on the expression 
levels of miRNAs in blood samples from patients in the 
hyperacute phase of ischemic stroke. Moreover, it is not 
clear whether changes in circulating miRNA expression 
are consistent with those in the brain ischemic penum‑
bra in cases of hyperacute ischemic stroke.
Therefore, we presume that specific blood miRNAs 
released from the brain ischemic penumbra may re‑
flect certain pathophysiological conditions of hy‑
peracute ischemic stroke, and some of these specific 
circulating miRNAs may be potential biomarkers for 
the early noninvasive diagnosis of ischemic stroke 
in the hyperacute stage, thereby helping clinicians 
choose efficient interventions and treatments. This 
study aims to explore the expression profiles of miR‑
NAs in the brain ischemic penumbra and blood of rats 
4 h after permanent middle cerebral artery occlusion 
(pMCAO) in order to investigate their potential value 
as biomarkers of this condition.
To the best of our knowledge, this is the first study 
aimed at investigating miRNA expression changes in 
the penumbra and blood of rats with hyperacute isch‑
emic stroke. We speculated that the rats with hyper‑
acute ischemic stroke would show abnormal expression 
of circulating miRNAs, which could serve as novel non‑
invasive biomarkers for the early detection of hyper‑
acute ischemic stroke.
In the present study, the brain ischemic penum‑
bra and blood miRNAs were measured in rats 4 h after 
pMCAO or a sham operation to test the hypothesis that 
blood concentrations of penumbra‑specific miRNAs are 
promising biomarkers for hyperacute ischemic stroke.
METHODS
Animals
Male Sprague‑Dawley rats (300±20 g) were obtained 
from the Animal Experiment Center of Guangxi Medi‑
cal University. The rats were housed in a light and tem‑
perature‑controlled room (23±0.5°C with 12 h of light 
and 12 h of dark) and given free access to commercial 
food and tap water. The rats, matched for weight in 
each experiment, were randomized into a brain isch‑
emia group (n=12) and a sham group (n=12). Body tem‑
perature was maintained at 37.0°C with a heating pad 
during all surgical procedures. All animals were han‑
dled according to the guidelines of the Institutional 
Animal Ethics Committee of Guangxi Medical Univer‑
sity. Ethical approval was obtained from the University 
Animal Ethics Committee prior to the start of the study. 
pMCAO and sham surgeries
The rats assigned to the brain ischemia group 
(n=12) were anesthetized. The right common carotid 
artery, internal common carotid artery and main trunk 
of the external carotid artery were exposed by blunt 
dissection. The right common carotid artery and exter‑
nal carotid artery were ligated with a silk suture, and 
a small opening was made in the common carotid ar‑
tery. A monofilament nylon suture (40 mm in length, 
Φ0.34‑Φ0.36 mm) was inserted into the common carot‑
id artery and then threaded through the right internal 
carotid artery to occlude the right middle cerebral ar‑
tery. The suture was anchored in place to cause pMCAO. 
After the surgery, the rats were returned to their cages 
to recover from anesthesia at room temperature. At 4 h 
after surgery, all rats were assessed for neurological 
miRNA‑223‑3p and let‑7b‑3p associated with the penumbra 207Acta Neurobiol Exp 2019, 79: 205–216
deficits. Immediately afterward, blood was drawn from 
the jugular vein, and brains were rapidly removed after 
the rats were anesthetized. In the sham‑operated con‑
trol group, all procedures were identical except that 
the monofilament was not inserted.
Neurological deficit scores
Neurological functional evaluations were performed 
after the rats fully awoke from anesthesia. Neurological 
function was assessed using the following 5‑point neuro‑
logical deficit scale: 0 = no neurological deficit; 1 = failure 
to fully extend the left forepaw; 2 = contralateral circling 
or walking; 3 = falling to the left but walking when stimu‑
lated; and 4 = unconsciousness, death or other state of un‑
responsiveness to stimulation (Longa et al., 1989). Scores 
were tallied separately for each animal. Rats receiving 
a score of 0, 1 or 4 were excluded from the study. In addi‑
tion, rats with cerebral hemorrhage were excluded.
Collection of ischemic penumbra tissue 
and peripheral blood
According to the experimental protocol, rats were 
anesthetized and their blood and penumbra tissue sam‑
ples were collected 4 h after pMCAO. Tissue samples 
from the brain ischemic penumbra were harvested as 
previously reported (Ashwal et al., 1998) (Fig. 1A) and 
stored at ‑80°C. Blood samples were drawn from the left 
or right jugular vein of each rat and collected in tubes 
containing ethylenediaminetetraacetic acid (EDTA).
Histopathologic analysis
Hematoxylin and eosin (H&E) staining was used to 
assess neuronal damage in the brain ischemic penum‑
bra after pMCAO in rats. H&E staining was performed 
according to standard protocols. The rats were anes‑
thetized at 4 h after pMCAO and transcardially per‑
Fig. 1. H&E staining showing the neuropathological changes in the ischemic penumbra after pMCAO. (A) A schematic representation of brain tissue from 
the ischemic penumbra. (B) H&E staining in the ischemic penumbra area from the sham group. (C) H&E staining in the ischemic penumbra area from the 
brain ischemia group. Brain tissue in the ischemic penumbra area was stained with H&E and observed under a microscope (×200 magnification).
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fused with 4% formalin. The brains were removed and 
postfixed in 10% formalin for 24 h. A two‑millime‑
ter‑thick sample of brain ischemic penumbra tissue, 
from the optic chiasm to 2 mm posterior, was obtained 
from each rat. The samples were then embedded in 
paraffin  blocks  and  cut  into  successive  3‑μm‑thick 
coronal sections. The sections were deparaffinized, 
stained with H&E and subsequently observed under 
a microscope.
Total RNA isolation from penumbra  
and blood samples
At 4 h after pMCAO or the sham procedure, all rats 
were anesthetized. Blood (2 ml) was drawn from the 
right or left jugular vein into EDTA‑containing tubes, 
and then the rats were euthanized. The brain was re‑
moved from each rat, and the tissue of the ischemic 
penumbra area was dissected as rapidly as possible, 
frozen, and stored at ‑80°C. Total RNA, including miR‑
NAs, was extracted from the ischemic penumbra tissue 
or blood with TRIzol Reagent (Invitrogen, CA, USA) fol‑
lowing the manufacturer’s protocol. Three milliliters 
of TRIzol was used per 1 ml of blood. The quantity and 
quality of the total RNA were measured by a Nanodrop 
ND‑2000  spectrophotometer.  OD260  was  used  to  cal‑
culate  the concentration, while  the OD260/OD230 and 
OD260/OD280 ratios were used to determine the purity 
of total RNA. Specifically, all of the OD260/OD280 ratios 
were between 1.8 and 2.0, while the OD260/OD230 ratio 
was greater than 1.6. The integrity of total RNA was as‑
sessed by electrophoresis on a 1% denaturing agarose 
gel and analysis by an Agilent 2200 Bioanalyzer (Agi‑
lent Technologies, USA). The Agilent 2200 TapeStation 
software was used to calculate the RNA integrity num‑
ber equivalent (RINe), an objective measurement of 
RNA degradation. The samples were immediately used 
or stored at ‑80°C for future use.
miRNA microarray profiling
miRNA microarray experiments were carried out by 
a service company (Guangzhou RiboBio Co. Ltd., China) 
according to the method described on the company’s 
website (http://www.ribobio.com/) using a miRNA ar‑
ray (RiboArray™ miDETECT TM Rat Array 1×12K, Guang‑
zhou  RiboBio  Co.  Ltd.,  China)  composed  of  765  probe 
sets from miRNAs registered in miRBase 21.0. The ex‑
pression data were subjected to median normalization. 
After normalization, significant differential expression 
of miRNAs between the brain ischemia group and the 
sham group was identified through fold changes (≥1.5) 
and p‑values (≤0.05). Hierarchical clustering was used 
to determine the distinguishable miRNA expression 
profiles among samples. A total of twelve samples were 
used, including three penumbra brain tissue samples, 
three sham samples from the corresponding area of the 
rat brain, three blood samples from ischemic rats and 
three blood samples from sham rats.
Detection of miRNA expression with qRT‑PCR
According to the results of the miRNA profiling 
analysis, the expression level of selected miRNAs in all 
the pMCAO‑ and sham‑treated rats was further con‑
firmed by quantitative real‑time polymerase chain 
reaction (qRT‑PCR). One microgram of total RNA was 
reverse transcribed into complementary DNA (cDNA) 
using a Mir‑X miRNA First‑Strand Synthesis Kit (Clon‑
tech Laboratories, Takara, Japan). qRT‑PCR was carried 
out on a LightCycler® 480 RT‑PCR system (Roche Ap‑
plied Science, Boehringer Mannheim, Germany) using 
SYBR Green master mix (Takara, Japan) according to 
the manufacturer’s instructions, and the results were 
analyzed with the LightCycler 480 Software 1.5.0. PCR 
amplification  was  conducted  in  a  25‑μl  reaction  vol‑
ume. The reactions were incubated in a 96‑well optical 
plate at 95°C for 10 sec, followed by 40 cycles at 95°C 
for 5 sec and 60°C for 20 sec. Samples were analyzed in 
triplicate, and all the PCR primers were obtained from 
TaKaRa Biotechnology  (Dalian, China). U6 was used as 
the internal standard control. The 2−ΔΔCt method was 
used to analyze miRNA expression.
Statistical analysis
Differential miRNA expression was identified on 
the  basis  of  the  following  three  conditions:  (1)  the 
miRNA was expressed in both penumbra and blood 
samples; (2) the difference in miRNA expression be‑
tween the brain ischemia group and the sham group 
was greater than or equal to a 1.5‑fold change in both 
the penumbra and blood; and (3) a Student’s t‑test be‑
tween the brain ischemia group and the sham group 
yielded a p‑value of less than 0.05 in both the pen‑
umbra and blood. The qRT‑PCR data were analyzed 
with  the  software  SPSS  16.0  (IBM,  USA).  Differenc‑
es between two independent groups were analyzed 
for statistical significance using a Student’s t‑test 
(two‑tailed). Differential expression was considered 
statistically significant at a p‑value <0.05 between the 
two groups. The correlation between miRNA expres‑
sion levels in the penumbra and blood was assessed 
using Pearson’s linear correlation analysis. Sensitivi‑
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ty, specificity and accuracy of miRNA were compared 
using receiver operating characteristic (ROC) analy‑
ses. The data are expressed as the mean ± standard 
error of the mean (SEM). All of the experiments were 
performed in triplicate.
RESULTS
Ischemic brain damage was induced by pMCAO
A total of 18 male rats were selected to establish 
brain ischemia models by pMCAO. Among these 18 rats, 
3 rats died, while the remaining 15 successfully mod‑
eled ischemia. Three rats that had a Bederson neurolog‑
ical score of 0 or 4 points were excluded. The other 12 
rats with a brain ischemia score between 2 and 3 were 
selected for the experiment. In addition, 12 rats were 
subjected to a sham operation. To identify any patho‑
logical changes, we examined the neuronal morpholo‑
gy in the ischemic penumbra area of the rat brain. H&E 
staining was used to observe histopathological changes. 
Our results showed that, compared with rats in the sham 
group, rats in the brain ischemia group sustained neu‑
ronal damage. Rats receiving sham surgery had normal 
microscopic features and no inflammatory infiltration 
from the brain ischemic penumbra area. The neurons 
and glial cells were normally shaped, had round, lightly 
stained nuclei and were arranged in an orderly fashion 
(Fig. 1B). Meanwhile, rats in the brain ischemia group 
displayed glial cell swelling and vacuolization, neuronal 
pyknosis and anachromasis, fragmentation, interstitial 
hyperemia and edema (Fig. 1C).
Identification of differentially expressed miRNAs 
by microarray analysis
Total RNA was extracted from brain tissues in the 
ischemic penumbra area and from blood, and spectro‑
photometry was used to assess RNA yield and quality. 
All brain and blood samples were of high quality and 
sufficient concentration (Fig. 2).  In total, 765 miRNAs 
were detected by miRNA microarray analysis. From 
the miRNA expression profiles, we identified miRNAs 
that were differentially expressed between the brain 
ischemia group (n=3) and the sham group (n=3). Hier‑
archical clustering was used to group miRNAs on the 
basis of their expression levels across samples (Fig. 3). 
Each column represents a sample, and each row rep‑
resents a miRNA. The color scale shown on the right 
illustrates the relative expression level of a miRNA 
in a given slide: red indicates a high relative gene ex‑
pression, and blue indicates a low relative gene ex‑
pression. The relative expression level of each miRNA 
in a single sample is depicted according to the color 
scale provided. We set thresholds of fold change>1.5 
and p‑value<0.05. In the ischemic penumbra area, 321 
miRNAs demonstrated at least 1.5‑fold change in ex‑
pression in the brain ischemia group compared with 
the sham group. Among these miRNAs, 6 were upreg‑
ulated, and 315 were downregulated in the penumbra 
4 h after pMCAO. In blood, 88 miRNAs demonstrated at 
least 1.5‑fold change in expression in the brain isch‑
emia group compared with the sham group. Among 
these miRNAs, 80 were upregulated, and 8 were down‑
regulated in blood 4 h after pMCAO.
Unique miRNA expression profiles in penumbra 
tissue and blood
First, we used Venn diagrams to analyze the com‑
mon miRNAs and the unique miRNAs between the sham 
group (n=3) and the brain ischemia group (n=3) in both 
blood and brain (Fig. 4A, C). As there may be miRNAs 
that are specifically regulated in hyperacute ischemic 
stroke, we looked for unique miRNA expression pro‑
files in the penumbra and blood using cluster analy‑
sis. This analysis showed that brain ischemic injury 
had a unique miRNA expression profile in both blood 
(Fig. 4B) and the penumbra (Fig. 4D). For the expression 
profiles shown, the expression profiles found in blood 
and the penumbra were not identical. The differential 
expression patterns of miRNAs between the sham and 
brain ischemia groups emphasize the uniqueness of the 
different miRNA responses of the blood and penum‑
bra to ischemic brain damage. The results showed that 
most miRNAs in the blood were up‑regulated and most 
miRNAs in penumbra were down‑regulated in rats 4 h 
after pMCAO. 
qRT‑PCR validation of several differentially 
expressed miRNAs in the penumbra and blood
We hoped to find a potential blood biomarker for 
the detection of brain ischemic damage. The biomark‑
er should be simultaneously detectable in the penum‑
bra tissue and blood and should be sensitive to isch‑
emic damage. More importantly, the expression trends 
of miRNAs in the penumbra and blood should be con‑
sistent. Thus, several miRNAs were selected from the 
miRNA profiling studies. However, some of those miR‑
NAs were not expressed in all samples. Therefore, only 
miR‑223‑3p and let‑7b‑3p were selected for further 
identification by qRT‑PCR. Our results show that in 
both penumbra and blood, miR‑223‑3p was confirmed 
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to be upregulated (Fig. 5A and 5B), while let‑7b‑3p was 
confirmed to be downregulated (Fig. 5C and 5D). The 
results of the qRT‑PCR analysis were essentially con‑
sistent with the miRNA microarray results.
Fig. 2. Validation of the quality of total RNA. (A) Agarose gel electrophoresis analysis showed that total RNA from blood had no obvious degradation and 
had a good degree of purity. (B) Agarose gel electrophoresis analysis showed that total RNA from brain tissue in the ischemic penumbra area had no 
obvious degradation and had a good degree of purity. (C) Agilent 2200 TapeStation software analysis showed high quality total RNA with RINe scores 
consistently greater than 7. (D) This RNA ladder is ideal for approximate RNA quantification on gels.
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Correlation analysis and ROC curve analysis was 
performed to evaluate the diagnostic value of 
blood miRNAs
First, in the correlation analysis, miR‑223‑3p 
(Fig. 6A) and let‑7b‑3p (Fig. 6B) expression levels in the 
penumbra and blood showed a moderate correlation 
for both the sham and brain ischemia groups. Next, 
we generated ROC curves to evaluate the potential di‑
agnostic value of blood miR‑223‑3p and let‑7b‑3p as 
biomarkers for hyperacute ischemic stroke. The ROC 
curve analysis revealed a significant diagnostic value 
of blood miR‑223‑3p (Fig. 7A) and let‑7b‑3p (Fig. 7B) for 
ischemic stroke in rats. This result suggests that blood 
miR‑223‑3p and let‑7b‑3p may be valuable biomarkers 
for diagnosing hyperacute ischemic stroke.
DISCUSSION
In the present study, we sought to investigate the 
expression of miRNAs in hyperacute ischemic stroke by 
analyzing miRNA expression profiles in the penumbra 
and blood 4 h postoperatively in pMCAO‑treated and 
sham‑operated control rats.
An important finding of this study is that signifi‑
cantly different miRNA expression profiles occurred 
in both the penumbra and blood after ischemic brain 
damage. Some of these miRNAs were significantly 
up‑or down‑regulated by more than 1.5‑fold in the pen‑
umbra and blood 4 h after pMCAO. Moreover, the levels 
of some miRNAs showed parallel patterns of expression 
in blood and the penumbra. These results suggest the 
possible use of circulating miRNAs as noninvasive bio‑
markers for hyperacute ischemic stroke. Our findings 
specifically identified candidate brain‑specific miRNAs 
that appear to be novel and stable biomarkers for hy‑
peracute ischemic stroke in rat.
A remarkable finding of this study is that 
miR‑223‑3p was upregulated in both the penumbra 
and blood 4 h after pMCAO‑induced ischemic stroke in 
rats. This result is consistent with previous findings 
that the expression level of miR‑223 in the blood of 
patients with acute ischemic stroke was significantly 
increased compared with that of the healthy controls 
(Wang et al., 2014). A recent study also demonstrat‑
Fig.  3. Hierarchical clustering of selected miRNAs that changed by more than 1.5‑fold, showing unique miRNA expression patterns in blood (A) and 
penumbra brain tissue (B) 4 h after pMCAO. This experiment was performed on two groups of rats, including a sham group (Blood – sham‑1, 2 and 3 and 
Brain – sham‑1, 2 and 3) and a brain ischemia group (Blood – 4 h‑1, 2 and 3 and Brain – 4 h‑1, 2 and 3). Each column represents a sample, while each row 
represents a miRNA.
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ed that the expression level of miR‑223 was greatly 
upregulated in the blood of young ischemic stroke 
patients aged 18 to 49 years (Tan et al., 2009). In ad‑
dition, correlation analysis demonstrated that the 
expression level of miR‑223‑3p in the brain ischemic 
penumbra was positively correlated with the blood 
miR‑223‑3p level in this rat model of hyperacute isch‑
emic stroke.
Moreover, several previous studies have indicat‑
ed that miR‑223 is selectively highly expressed in im‑
mune cells and that this miRNA plays a crucial role in 
regulating cell cycle progression and cell proliferation 
(Johnnidis et al., 2008; Tsitsiou and Lindsay, 2009). A re‑
cent study suggested that miR‑223 is closely correlated 
with acute ischemic stroke and may play a crucial role 
in stroke by upregulating the insulin‑like growth factor 
Fig. 4. Venn diagrams showing the numbers of miRNAs that were differentially expressed between the sham group and the brain ischemia group in both 
brain and blood. In addition, some miRNAs are stably expressed in both brain and blood 4 h after ischemic brain damage (A, C). The difference between 
the sham group and the brain ischemia group in the miRNA expression pattern in blood (B). The difference between the sham group and brain ischemia 
group in the miRNA expression pattern in brain tissue from the ischemic penumbra area (D). Green dots indicate that the expression levels of miRNAs are 
down‑regulated, blue dots indicate no change and red dots indicate up‑regulation.
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gene (Wang et al., 2014). Another study demonstrated 
that platelet‑released miR‑223 promotes advanced gly‑
cation end products, leading to vascular endothelial 
cell apoptosis by targeting the insulin‑like growth fac‑
tor receptor (Pan et al., 2014). According to the com‑
prehensive analysis above, our findings suggest that 
miR‑223‑3p may be involved in the pathological pro‑
cess of hypoxia‑ischemia; furthermore, they indicate 
that circulating blood miR‑223‑3p levels may represent 
changes in miR‑223‑3p levels in the brain ischemic pen‑
umbra in response to hyperacute ischemic stroke.
Another important finding of this study was that the 
expression of let‑7b‑3p was downregulated in both the 
penumbra and blood 4 h after pMCAO. This finding is con‑
sistent with the results of many previous studies. A recent 
study showed that the plasma let‑7b level was decreased 
Fig. 5. The expression of miRNAs in the penumbra and blood of rats 4 h after pMCAO. (A) The expression level of miR‑223‑3p in the blood 4 h after pMCAO. 
(B) The expression level of miR‑223‑3p in the penumbra 4 h after pMCAO. (C) The expression of let‑7b‑3p in the blood 4 h after pMCAO. (D) The expression 
of let‑7b‑3p in the penumbra 4 h after pMCAO. (A, B) miR‑223‑3p was found to be highly expressed in both the penumbra and blood at 4 h after pMCAO. 
(C, D) let‑7b‑3p was found to have low expression in both the penumbra and blood 4 h after pMCAO. *p<0.01 vs. the sham group.
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in ischemic stroke patients with large artery atherosclero‑
sis (Long et al., 2013). Another study showed that the ex‑
pression of let‑7b was significantly decreased in patients 
with ischemic stroke compared with healthy controls 
(Sepramaniam et al., 2014). In 2000, the let‑7 family was 
found to play important roles in regulating the cell cycle, 
apoptosis, proliferation, migration and immunity (Pas‑
quinelli et al., 2000; Reinhart et al., 2000). let‑7b was also 
found to be differentially expressed  in the pathophysio‑
logical process of ischemic stroke, and it may thus play 
key roles  in angiogenesis,  inflammation and neurogene‑
sis (Pasquinelli et al., 2000). Moreover, a previous study 
demonstrated that let‑7b activates toll‑like receptor (TLR) 
7, which contributes to the spread of central nervous sys‑
tem injury. Specifically, it was found that let‑7b is a crucial 
activator of TLR7 in both neurons and immune cells. That 
study characterized TLR7 expression in neurons and es‑
tablished a new role for TLR7 as a receptor that regulates 
neuronal death. The investigators also speculated that 
let‑7b is released during pathological processes and stim‑
ulates TLR7, thereby sending a danger signal to neurons 
and accelerating their decay (Lehmann et al., 2012). In 
general, members of the let‑7 family may function as im‑
portant regulatory molecules in the pathophysiology of 
ischemic stroke. Our correlation analysis also demonstrat‑
ed that the expression level of let‑7b‑3p in the penumbra 
Fig. 7. Diagnostic value of blood miR‑223‑3p and let‑7b‑3p in rats 4 h after pMCAO. (A) Sham group vs brain ischemia group; the AUC for blood miR‑223‑3p 
was 0.9688 (95% CI: 0.9172~1.020). (B) Sham group vs brain ischemia group; the AUC for blood let‑7b‑3p was 0.9180 (95% CI: 0.8226~1.013).
Fig.  6. Correlation analysis and ROC analysis were used to study the diagnostic value of blood miR‑223‑3p and let‑7b‑3p for ischemic stroke in rats. 
(A) Correlation analysis of the expression levels of miR‑223‑3p between the penumbra and blood (r=0.740*, p<0.001). (B) Correlation analysis of the 
expression levels of let‑7b‑3p between the penumbra and blood (r=0.665**, p<0.001). 
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was positively correlated with the level in the blood af‑
ter ischemic brain damage. Our data suggest that chang‑
es in let‑7b‑3p in the blood represent similar changes in 
the penumbra. However, the exact reason why let‑7b‑3p 
levels are decreased at 4 h after ischemic brain damage is 
not clear; the cause of this reduction of let‑7b‑3p in both 
the penumbra and blood after ischemic brain damage de‑
serves further investigation.
In conclusion, our results show that the blood lev‑
els of miR‑223‑3p and let‑7b‑3p are correlated with the 
levels in the penumbra of an ischemic brain lesion, sug‑
gesting that changes in blood miR‑223‑3p and let‑7b‑3p 
levels may represent changes in the corresponding 
penumbra miRNA levels. The diagnostic performance 
of these miRNAs in rats was measured by ROC analysis, 
which indicated that miR‑223‑3p (AUC was 0.9688) and 
let‑7b‑3p (AUC was 0.9180) are useful for distinguishing 
the brain ischemia group from sham group. Therefore, 
our study provides evidence that circulating miR‑223‑3p 
and let‑7b‑3p might be novel noninvasive biomarkers 
for the diagnosis of hyperacute ischemic stroke.
However, this study has some limitations. First, al‑
though we found that blood miR‑223‑3p and let‑7b‑3p 
levels are associated with the levels of those miRNAs 
in the brain ischemic penumbra in rats, there is no di‑
rect evidence that the circulating miRNAs were initially 
released from the ischemic penumbra or that the miR‑
NAs caused the outcome. Second, in order for a circu‑
lating biomarker to be useful in diagnosing hyperacute 
ischemic stroke, there must be a very rapid test for the 
marker. The techniques we used in this study need to 
be modified and improved to increase their clinical ap‑
plicability. Finally, our findings need to be validated in 
a human randomized clinical trial with a large cohort of 
hyperacute ischemic stroke patients.
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